Since we observe that the ID2 (corepressor)-ETS2 (transcription factor) axis regulate the acquisition of the microglial tumour-supportive phenotype upon stimulation by glioma cancer cells, and that the expression of both ID2 and ETS2 genes were validated in tumour-associated microglia/macrophages isolated from glioblastoma tumours, we decided to investigate whether ID2 gene expression levels, as well as the expression of the transcription factor regulated by ID2, i.e., ETS2, could be used as survival prognostic factors for patients suffering from glioma. This evidence concerns the gene ETS2 and central nervous system cancer.